肺癌病理表型转化的预测模型及分子机制研究

批准号:
81472206
项目类别:
面上项目
资助金额:
80.0 万元
负责人:
赵军
依托单位:
学科分类:
H1813.肿瘤诊断
结题年份:
2018
批准年份:
2014
项目状态:
已结题
项目参与者:
赵军、白桦、卓明磊、苏哲、王书航、杨晓丹、李振祥、仲佳、于江泳
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
肺癌的发病率和死亡率在各恶性肿瘤中均居于前列,并呈逐年上升趋势。大部分肺癌诊断时已处于晚期,以表皮生长因子受体酪氨酸激酶抑制剂(Epithelial growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)为代表的分子靶向治疗是主要的治疗手段之一。病理表型转化是EGFR-TKI耐药的重要原因之一。由于耐药后二次活检不易获得且不作为临床常规,很可能低估这一耐药机制所占的比例。因此,我们拟在前期基因组拷贝数变异(Genome-wide copy number variations, GW-CNVs)研究的基础上,利用隐马尔可夫模型联合谱系聚类法,建立基于外周血游离DNA的肺癌病理表型无创预测模型,以期实现肺癌病理表型转化的无创性适时监测。并借助GW-CNVs及转录组学研究肺癌表型转化的分子机制及与EGFR-TKI耐药的相关性。
英文摘要
Lung cancer is the leading cause of cancer related death whether worldwide or in China with an increasing trend. Most of patients with lung cancer were advanced stage in initial diagnosis. Molecular targeted therapy such as EGFR-TKIs (Epithelial growth factor receptor tyrosine kinase inhibitors) is one of the main strategies. However, pathological phenotype transformation is one of the important reasons for EGFR-TKI resistance, the frequency of which might be underestimated because a secondary biopsy is not easy to obtain in clinical practice. In our previous study, we had explored the usefulness of GW-CNVs (Genome-wide copy number variations) in differentiating pathological phenotype of lung cancer. Further, we will establish noninvasive predicting model for lung cancer phenotype in free DNA of peripheral blood, through a method combined with Hidden Markov Model(HMM) model and hierarchical cluster analysis. Moreover, we will study the molecular mechanisms of phenotypic transformation on the basis of GW-CNVs and transcriptiomics, especially focusing on the transformation of lung adenocarcinoma with EGFR mutations to small cell carcinoma after EGFR-TKI resistance. The aims of the study are constructing noninvasive method monitoring phenotypic transformation, and providing potential targets theoretical basis to overcome the clinical phenotype transformation.
本研究对非小细胞肺癌小细胞转化的组织及体液标本进行二代测序,发现了转化前后的差异基因,初步明确肺腺癌转化为小细胞癌的分子发生基础及导致表型转化的关键基因组群。同时对比了体液及组织标本的一致性,建立基于外周血游离DNA 的肺癌病理表型无创预测模型,为肺癌小细胞转化无创模型的建立提供了理论基础。同时建立小细胞转化的细胞模型,为后续进一步研究创造条件。本研究还对穿刺小标本移植瘤模型的构建及一致性进行了方法学的研究,为后续此类研究建立了成熟的方法。本研究提高对肺癌病理表型转化导致治疗失败的认知度,并为实现更精准的肺癌“个体化”治疗提供研究基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
复发性高级别上皮性卵巢癌患者肿瘤进展后持续抗血管生成治疗:I 期试验经验
DOI:10.18632/oncotarget.9048
发表时间:2016-06-07
期刊:Oncotarget
影响因子:--
作者:Hou MM;Wang Z;Janku F;Piha-Paul S;Naing A;Hong D;Westin S;Coleman RL;Sood AK;Tsimberidou AM;Subbiah V;Wheler J;Zinner R;Lu K;Meric-Bernstam F;Fu S
通讯作者:Fu S
DOI:doi: 10.1002/cam4.956
发表时间:2016
期刊:Cancer Medicine
影响因子:4
作者:Zhijie Wang;Naiyi Shi;Aung Naing;Filip Janku;Vivek Subbiah;Dejka M. Araujo;Shreyaskumar R. Patel;Joseph A. Ludwig;Lois M. Ramondetta;Charles F. Levenback;Pedro T. Ramirez;Sarina A. Piha-Paul;David Hong;Daniel D. Karp;Apostolia M.Tsimberidou;Funda Meric-Be
通讯作者:Funda Meric-Be
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
转移性平滑肌肉瘤患者的生存:MD安德森临床中心靶向治疗经验
DOI:10.1002/cam4.956
发表时间:2016-12
期刊:Cancer medicine
影响因子:4
作者:Wang Z;Shi N;Naing A;Janku F;Subbiah V;Araujo DM;Patel SR;Ludwig JA;Ramondetta LM;Levenback CF;Ramirez PT;Piha-Paul SA;Hong D;Karp DD;Tsimberidou AM;Meric-Bernstam F;Fu S
通讯作者:Fu S
Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade
DNA 损伤反应途径中的突变可作为免疫检查点阻断的潜在生物标志物
DOI:10.1158/0008-5472.can-18-1814
发表时间:2018-11-15
期刊:CANCER RESEARCH
影响因子:11.2
作者:Wang, Zhijie;Zhao, Jing;Wang, Jie
通讯作者:Wang, Jie
Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases
多区域测序揭示骨肉瘤和匹配肺转移瘤的遗传异质性和进化史
DOI:10.1158/0008-5472.can-18-1086
发表时间:2019-01-01
期刊:CANCER RESEARCH
影响因子:11.2
作者:Wang, Di;Niu, Xiaohui;Wang, Jie
通讯作者:Wang, Jie
HDGF介导CAFs促进NSCLC肿瘤干细胞维持在化疗耐药中的功能和机制研究
- 批准号:--
- 项目类别:面上项目
- 资助金额:55万元
- 批准年份:2020
- 负责人:赵军
- 依托单位:
国内基金
海外基金
